On the other hand, cabozantinib exerts its effect inhibiting proteins involved in regulation of extracellular matrix (ECM) remodelling and tumour invasiveness and motility (SDF1, MMP2 and HGF) by cancer-associated fibroblasts (CAFs; Table 3, Tables 5–6, Figure 3, Supplementary Figures 1–5, Supplementary Tables 5–9). This evidence concerns the gene CXCL12 and cancer.